The purpose of this sub-study of the Outcome Reduction with Initial Glargine Intervention ( ORIGIN ) trial was to determine efficacy and safety of targeting normal fasting plasma glucose ( FPG ) levels in patients with early Type 2 diabetes treated with insulin glargine in comparison with standard care .
